Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Piper Sandler raised its price target on Solventum (NYSE:SOLV) to $94.00 from $87.00 on Friday, while maintaining an Overweight rating following the company’s strong second-quarter performance. The $12.45 billion healthcare company, currently trading at $71.95, sits within analysts’ target range of $73-$103, according to InvestingPro data.
Solventum reported second-quarter revenue of $2,161 million, representing 2.8% organic growth, and earnings per share of $1.69, which exceeded consensus expectations. The results marked another quarter of solid performance for the healthcare company, which has maintained profitability over the last twelve months with an EBITDA of $1.416 billion.
Piper Sandler highlighted Solventum’s growing execution track record as a key factor in its decision to upgrade the stock a few months ago. The firm noted that management flowed through the second-quarter outperformance to its full-year guidance.
The research firm expressed that it’s becoming "increasingly difficult for medtech investors to ignore the improving underlying performance and pathway to shareholder value creation" that Solventum’s management team is developing.
Piper Sandler anticipates core earnings upside for the remainder of the year and sees additional opportunities for positive estimate revisions in the future, particularly associated with debt reduction following the P&F sale.
In other recent news, Solventum Corp reported its second-quarter earnings for 2025, exceeding analysts’ expectations. The company posted an adjusted earnings per share of $1.69, just above the projected $1.68. Solventum’s revenue reached 2.2 billion dollars, marking a 3.9% increase. These financial results were a significant development for the company. Analyst firms have taken note of Solventum’s performance, although specific upgrades or downgrades were not mentioned. These earnings figures are crucial for investors looking to understand the company’s current financial health. The recent developments highlight Solventum’s ability to meet and slightly surpass market expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.